Advancing Regulatory Pathways in China

A central focus of the trip will be advancing the company's ongoing regulatory approval process with the National Medical Products Administration (NMPA) in China. Meetings with regulators, clinical partners, and key stakeholders are expected to stimulate progress toward approval and align on the final steps required for market entry. Sensodetect views NMPA approval as a critical milestone for expanding access to its breakthrough neurodiagnostic tools in the world's second-largest healthcare market.

Joint Venture and Investment Discussions

In parallel, the company will engage in joint venture discussions with leading Chinese investment and healthcare groups. These talks aim to give a large capital infusion and establish a long-term strategic collaboration that supports not only commercialization in China but also future research, development, and manufacturing partnerships in the region.

Next-Generation Technology

During the mission, Sensodetect will showcase its next version of its hardware in combination with its newly developed AI solution. This integrated approach is designed to enhance diagnostic accuracy, speed, and clinical usability.

Looking ahead, Sensodetect is also laying the foundation for it's next generation solution that combines ABR with ERP (EEG). This innovation represents a major step toward a more comprehensive neurodiagnostic platform, providing clinicians with deeper, objective insights into brain function.

Market Expansion in the Middle East

Following China, the Sensodetect team will visit the Middle East for business discussions with healthcare providers, distributors, and policymakers. The region presents strong demand for innovative diagnostic solutions, and the company sees significant opportunities to contribute to improved mental healthcare outcomes.

New Product Launch Timelines

The international mission will also serve as a platform for advancing discussions around product launch timelines. Sensodetect plans to align with regional partners on distribution strategies, market readiness, and clinical adoption to ensure a successful roll-out in both China and the Middle East.